Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharmaceutical symbols : LLY save search
Lilly Edges Out J&J to Top 20 BioPharma Market Cap List for 2023
Published: 2024-02-20 (Crawled : 17:00) - biospace.com/
MS | News 0 d | $90.26 0.2% -0.31% 5.1M
|
Finance
|
| O: -0.65%
H: 0.64%
C: -0.69%
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 1.02%
H: 0.43%
C: -4.35%
biopharma market
REVALESIO ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 RESCUE STUDY OF RNS60 IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN LATE-BREAKING ORAL PRESENTATION AT ISC 2024
Published: 2024-02-07 (Crawled : 23:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
rns60 stroke presentation positive topline study
Lilly Launches Direct-to-Consumer Website, Services to Support Weight-Loss Drugs
Published: 2024-01-05 (Crawled : 17:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.08%
H: 0.97%
C: 0.74%
services
Lilly Declares Fourth-Quarter 2023 Dividend
Published: 2023-11-01 (Crawled : 11:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -2.76%
H: 0.0%
C: 0.0%
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
Published: 2023-10-03 (Crawled : 12:00) - biospace.com/
PNT | $13.68 2.63% 0.15% 0
|
|
| O: 85.39%
H: 0.81%
C: 0.41%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
biopharma acquire
U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer
Published: 2023-10-02 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: 0.0%
drug food response
Forbion co-leads $175 million Series B financing of Mariana Oncology as first investment of Forbion Ventures Fund VI
Published: 2023-09-07 (Crawled : 12:00) - biospace.com/
NAMS | $19.44 -3.04% -3.27% 220K
|
n/a
|
| O: -0.09%
H: 0.09%
C: -4.54%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.76%
H: 2.15%
C: 1.6%
REPL | $6.98 -3.19% -3.3% 1.1M
|
Health Technology
|
| O: 1.0%
H: 0.3%
C: -2.58%
series
Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554
Published: 2023-03-02 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.76%
H: 1.45%
C: 1.05%
cftx-1554 global therapeutics agreement
Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
Published: 2022-10-06 (Crawled : 11:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -1.16%
H: 3.45%
C: 1.53%
treatment fda designation fast track designation obesity tirzepatide
Eli Lilly Q2: Down 4% as Government Pushes on Insulin Prices, Forced to Pay $61 Million Fine
Published: 2022-08-04 (Crawled : 15:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -1.16%
H: 0.02%
C: -1.42%
insulin
Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements
Published: 2022-08-04 (Crawled : 11:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -1.16%
H: 0.02%
C: -1.42%
momentum
BioSpace Movers & Shakers, Oct. 22
Published: 2021-10-22 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: -0.41%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.09%
H: 1.28%
C: 1.16%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: 0.37%
H: 1.06%
C: 0.96%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
OCUL | News | $5.86 -22.69% -29.35% 6.1M
|
Health Technology
|
| O: -27.15%
H: 0.89%
C: -12.42%
NRIX 2 d | $14.43 2.49% 2.43% 970K
|
Health Technology
|
| O: 0.43%
H: 0.11%
C: -0.81%
GILD | News | $66.16 -1.15% -1.16% 4.9M
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: 0.0%
space spac
Lilly's Longest Diabetes Drug Trial Lowers A1C and Increases Weight Loss
Published: 2021-10-19 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.03%
H: 1.46%
C: 1.36%
weight loss diabetes drug trial
Hemogenyx Pharmaceuticals Announces CDX Licence Agreement
Published: 2021-10-13 (Crawled : 10:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.55%
H: 1.64%
C: 1.01%
license
Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
ford test injection insulin
BioSpace Movers & Shakers, Sept. 10
Published: 2021-09-10 (Crawled : 13:15) - biospace.com/
VECT | $16.85 0.12% 130K
|
Professional, Scientific, and T...
|
| O: -1.15%
H: 4.09%
C: 1.82%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.92%
H: 0.7%
C: -1.11%
TRVN | $0.366 -8.96% -10.05% 1.2M
|
Health Technology
|
| O: 2.44%
H: 0.79%
C: -0.79%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.16%
H: 0.0%
C: 0.0%
space spac
Innovent Announces the Establishment of the Scientific Advisory Board
Published: 2021-08-09 (Crawled : 07:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.33%
H: 3.2%
C: 0.98%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.97%
H: 0.23%
C: -0.18%
Boehringer, Lilly: Jardiance Significantly Reduced CV Death and HF-Related Hospitalization in HFpEF
Published: 2021-07-06 (Crawled : 19:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.69%
H: 0.83%
C: 0.77%
Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference
Published: 2021-06-03 (Crawled : 22:00) - biospace.com/
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: -0.05%
H: 1.1%
C: 1.1%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.07%
H: 2.34%
C: 1.86%
ALNY | News | $145.16 -0.11% -0.19% 400K
|
Health Technology
|
| O: -0.72%
H: 4.77%
C: 3.86%
conference
Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial
Published: 2021-05-20 (Crawled : 11:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.33%
H: 1.99%
C: 1.2%
diabetes risk cardiovascular insulin cardio trial glargine tirzepatide
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.